<DOC>
	<DOCNO>NCT00057980</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell stop blood flow tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining celecoxib epirubicin may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose epirubicin give together celecoxib see well work treat patient hepatocellular carcinoma ( liver cancer ) .</brief_summary>
	<brief_title>Epirubicin Celecoxib Treating Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose epirubicin administer celecoxib patient hepatocellular carcinoma . - Determine response rate patient treat regimen . - Determine 6-month overall survival patient treat regimen . - Determine toxicity profile regimen patient . - Determine effect regimen serum level vascular endothelial growth factor correlate effect response patient . - Correlate expression cyclooxygenase-2 tumor tissue nonmalignant liver tissue response patient treat regimen . OUTLINE : This dose-escalation study epirubicin . - Phase I : Patients receive epirubicin IV 20 minute day 1 oral celecoxib twice daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-5 patient receive escalate dos epirubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 3 5 patient experience dose-limiting toxicity . - Phase II : Additional patient accrue treated phase I MTD epirubicin . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-52 patient ( 3-15 phase I 12-37 phase II ) accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis localize metastatic hepatocellular carcinoma ( HCC ) 1 follow : Biopsy Alphafetoprotein ( AFP ) measurement ( great 400 ng/mL hepatitis B surface antigen [ HBsAg ] negative OR great 1,000 ng/mL HBsAg positive ) Not amenable surgical resection liverdirected therapy Measurable evaluable disease* NOTE : *Changes AFP alone sufficient ChildPugh score A B PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 75,000/mm^3 Hepatic Bilirubin great 3.0 mg/dL AST great 5 time upper limit normal Renal Creatinine great 2.0 mg/dL Cardiovascular LVEF great 45 % MUGA echocardiogram Other Not pregnant nursing Fertile patient must use effective contraception No requirement nonsteroidal antiinflammatory drug ( NSAIDs ) except lowdose ( 81 mg ) aspirin No known hypersensitivity aspirin NSAIDs No contraindication cyclooxygenase2 ( COX2 ) inhibitor therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy HCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>